Iowa Medicaid coverage for Zepbound (Weight Loss)

Requests for weight loss, which is not a covered diagnosis of use, will be denied.

Policy note: Zepbound (tirzepatide for weight management/OSA) falls under the Anti-Diabetics, Non-Insulin Agents section insofar as it is a GLP-1/GIP RA. The policy explicitly states: 'Requests for weight loss, which is not a covered diagnosis of use, will be denied.' The OSA indication is not addressed by this document; only weight_loss is explicitly excluded. The OSA indication entry is omitted per rule 28 (silence is not denial).

Policy effective June 1, 2026 · verified June 4, 2026 · source: policy-387.html